850 patients signed up for an Alzheimer’s trial needing 760. For a biotech betting everything on one pill, that’s the good kind of surprise.
Trial enrollment is the part of drug development nobody writes headlines about. It’s slow, unglamorous and it’s also where a lot of promising drugs quietly die, not because the science failed, but because not enough patients showed up. So when Annovis Bio said this month that its pivotal Alzheimer’s trial had blown past its recruitment target, that’s a real win, even with the bigger questions still unanswered.
The Pennsylvania-based biotech reported its second-quarter 2026 results on 14 August, and the headline number was enrollment: 850 patients in its Phase 3 trial of buntanetap, an experimental once-daily pill for Alzheimer’s and Parkinson’s [1]. The original target was 760. Annovis beat it by 90 patients, and did it in a trial with strict entry rules; participants had to test positive for a specific blood marker tied to Alzheimer’s, not just show memory symptoms.
Most Alzheimer’s drugs on the market or in late-stage testing go after a single culprit, usually amyloid, the sticky protein that clumps in the brains of Alzheimer’s patients. Buntanetap doesn’t work that way. It’s designed to turn down production of several harmful proteins at once: amyloid and tau in Alzheimer’s, and a protein called alpha-synuclein that drives Parkinson’s. One mechanism, multiple diseases, a single daily pill.
That’s the pitch, anyway. It hasn’t been proven yet. The trial is measuring two things over 18 months: whether the drug helps memory and thinking in the near term, and whether it can slow the disease long-term, which is the much harder question to answer. Both outcomes are still ahead of the company, and it’s worth staying skeptical until the data actually lands.
Annovis CEO Maria Maccecchini highlighted the significance of the moment, announcing that the company had achieved a major milestone by fully enrolling 850 patients in its pivotal Phase 3 study for early Alzheimer’s disease. She noted that such strong participation reflects both the urgent need among patients and families for new therapeutic options and their trust in the company’s approach to treating the condition.
“We also plan to continue the ongoing study with an open-label extension so AD patients can continue buntanetap treatment after finishing the trial. With topline data on track for early 2027, our team has already begun preparing for regulatory submission so that we are ready to move once the results are in hand,” she added.
Alongside the Alzheimer’s study, Annovis is running a separate Parkinson’s trial that’s earlier in its recruitment. So far it has 266 of a targeted 500 patients, spread across 26 sites in the U.S., with full enrollment expected by the end of the year. It’s a longer haul, too: three years of follow-up, tracking safety and effectiveness using digital symptom monitoring and skin biopsies, tools that would have sounded like science fiction in Parkinson’s research a decade ago.
Enrollment numbers are the story investors want to hear. The balance sheet tells a different one. Annovis had $18.7 million in cash as of 30 June, down from $19.5 million at the start of the year. Research spending nearly tripled year over year, from $5.2 million to $12 million for the quarter, as the trial scaled up. Net loss for the quarter came in at $14.8 million, versus $6.2 million a year earlier.
None of that is alarming on its own; running a large Phase 3 trial is expensive by definition. But it’s a reminder that “fully enrolled” is a milestone, not a finish line. There are still years of data collection, analysis and regulatory review standing between where Annovis is now and an actual approved drug.
The company also promoted Dr Cheng Fang to Chief Scientific Officer this quarter, putting her in charge of the science as it heads toward its next real test: a database lock for six-month results in early 2027, followed by longer-term data a year after that.
Alzheimer’s and Parkinson’s aren’t just diseases that shorten life; they’re the diseases that decide whether extra years are actually worth having. A treatment that could slow either one wouldn’t just add time; it would add time spent thinking clearly, recognizing family and moving through the world without help. That’s the part of longevity science that’s easy to overlook when the conversation drifts toward biohacking and supplements: the biggest gains in healthy years left will probably come from unglamorous, hard-fought trials like this one.
Buntanetap hasn’t earned the benefit of the doubt yet. Annovis knows that, which is why the real verdict comes in 2027. However, over-enrolling a trial this large, with strict entry criteria, is a genuine signal that patients and their families are willing to bet on it, and that’s worth paying attention to.
